Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neurostem
- Development stage
- Phase 1
- Lead developer
- Medipost
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal, Intracerebral, Intravenous, Intraspinal
01
Overview
NEUROSTEM is an allogeneic stem cell therapy consisting of human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs). Developed by the South Korean biotechnology company MEDIPOST, it is primarily being evaluated for the treatment of Alzheimer's disease. The therapy is designed to be administered directly into the brain's ventricles (intraventricularly) via an Ommaya reservoir. Its mechanism of action involves the secretion of various paracrine factors that promote the clearance of amyloid-beta plaques, reduce the hyperphosphorylation of tau proteins, and modulate neuroinflammation. Clinical studies, including Phase 1 and Phase 2a trials, have evaluated its safety and potential to slow cognitive decline in patients with dementia of the Alzheimer's type. Preclinical research has also explored the potential of these cells in other indications such as glioblastoma and rheumatoid arthritis.
- Brand names
- NEUROSTEMNEUROSTEM-AD
- Other names
- Human Umbilical Cord Blood Derived Mesenchymal Stem CellshUCB-MSCs
Beyond the preview
Go deeper on neurostem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neurostem.